title: Therapeutic potential of anti-IL-1β IgY in guinea pigs with allergic asthma induced by ovalbumin.
abstract: BACKGROUND
  Interleukin-1 beta (IL-1β) plays pivotal roles in the progression of allergic airway inflammation. This study aims to determine whether the blockade of IL-1β can inhibit airway inflammation in guinea pigs with allergic asthma induced by the inhalation of aerosolized ovalbumin (OVA).
  
  
  METHODS
  Healthy guinea pigs treated with saline were used as normal controls (group C). The guinea pigs with allergic asthma induced by the inhalation of aerosolized OVA were randomly divided into three groups: (1) the M group containing negative control animals treated with saline; (2) the Z1 group containing animals treated by the inhalation of atomized 0.1% anti-IL-1β immunoglobulin yolk (IgY); and (3) the Z2 group containing positive control animals that were treated with budesonide. The inflammatory cells in the peripheral blood (PB) and bronchoalveolar lavage fluid (BALF) were evaluated using methylene blue and eosin staining. Cytokine concentrations were measured using an enzyme-linked immunosorbent assay. Pulmonary sections were examined using hematoxylin-eosin staining.
  
  
  RESULTS
  Allergic inflammation and damage to the pulmonary tissues were decreased in the Z1 group compared to the M group. Eosinophils and neutrophils in the PB and BALF were significantly decreased in the Z1 group compared to the M group (P<0.05). Treatment with anti-IL-1β IgY significantly reduced the levels of IL-1β, IL-4, IL-8, IL-13, TNF-α, TGF-β1 and IgE in the BALF (P<0.05).
  
  
  CONCLUSIONS
  The inhalation of aerosolized anti-IL-1β IgY inhibits pathological responses in the pulmonary tissues of guinea pigs with allergic asthma. The inhibitory activity may be due to the decrease in the numbers of eosinophils and neutrophils and the reduced levels of inflammatory cytokines and IgE in the PB and BALF.
authors.affiliation: Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
authors.forename: Hu
authors.initials: H
authors.lastname: Wei-xu
authors.affiliation: Institute of Clinical Medical Sciences, Jiangxi Province People's Hospital, Nanchang 330006, China.
authors.forename: Xiang
authors.initials: X
authors.lastname: Qin
authors.affiliation: Department of Hematology, Jiangxi Academy of Medical Science, Nanchang 330006, China.
authors.forename: Wen
authors.initials: W
authors.lastname: Zhu
authors.affiliation: Institute of Clinical Medical Sciences, Jiangxi Province People's Hospital, Nanchang 330006, China.
authors.forename: Chen
authors.initials: C
authors.lastname: Yuan-yi
authors.affiliation: Institute of Clinical Medical Sciences, Jiangxi Province People's Hospital, Nanchang 330006, China.
authors.forename: Zeng
authors.initials: Z
authors.lastname: Li-feng
authors.affiliation: Department of Experimental Animal, Institute of Occupational Medicine of Jiangxi, Nanchang 330006, China.
authors.forename: Liu
authors.initials: L
authors.lastname: Zhi-yong
authors.affiliation: Institute of Clinical Medical Sciences, Jiangxi Province People's Hospital, Nanchang 330006, China.
authors.forename: He
authors.initials: H
authors.lastname: Dan
authors.affiliation: Institute of Clinical Medical Sciences, Jiangxi Province People's Hospital, Nanchang 330006, China.
authors.forename: Wu
authors.initials: W
authors.lastname: Xiao-mu
authors.affiliation: Institute of Clinical Medical Sciences, Jiangxi Province People's Hospital, Nanchang 330006, China. Electronic address: hgz56@126.com.
authors.forename: Hu
authors.initials: H
authors.lastname: Guo-zhu
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology / Q000276:immunology; D019819:Budesonide / Q000627:therapeutic use; D016207:Cytokines / Q000097:blood; D004195:Disease Models, Animal; D004804:Eosinophils / Q000276:immunology; D006168:Guinea Pigs; D007073:Immunoglobulin E / Q000097:blood; D007136:Immunoglobulins / Q000627:therapeutic use*; D007249:Inflammation / Q000139:chemically induced / Q000276:immunology; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors* / Q000276:immunology; D008297:Male; D009504:Neutrophils / Q000276:immunology; D010047:Ovalbumin
chemical_list: D000893:Anti-Inflammatory Agents; D016207:Cytokines; C016512:IgY; D007136:Immunoglobulins; D053583:Interleukin-1beta; D007073:Immunoglobulin E; D019819:Budesonide; D010047:Ovalbumin
keywords: AHR; Allergic asthma; BALF; Cytokines; Guinea pigs; HE; IL-1 receptor antagonist; IL-13; IL-1ra; IL-1β; IL-4; IL-8; IgE; IgY; Immunoglobulin yolk; Infliximab; Interleukin-1β; OVA; Omalizumab; PB; T helper type 2; TGF-β(1); TNF-α; Th2; airway hyperresponsiveness; anti-IgE antibody; anti-TNF-α antibody; bronchoalveolar lavage fluid; hematoxylin-eosin; immunoglobulin E; immunoglobulin yolk; interleukin-13; interleukin-1beta; interleukin-4; interleukin-8; ovalbumin; peripheral blood; sRaw; sTNFR; soluble TNF-α receptor; specific airway resistance; transforming growth factor-beta 1; tumor necrosis factor-alpha